116 related articles for article (PubMed ID: 23687702)
1. [Is dyslipidemia a risk factor in patients treated with antiretroviral drugs?].
Soska V
Vnitr Lek; 2008 Feb; 54(2):135-6. PubMed ID: 23687702
[No Abstract] [Full Text] [Related]
2. Dyslipidemia related to antiretroviral therapy.
Estrada V; Portilla J
AIDS Rev; 2011; 13(1):49-56. PubMed ID: 21412389
[TBL] [Abstract][Full Text] [Related]
3. Treating antiretroviral-induced dyslipidemia in HIV-infected adults.
Scordo KA
Nurse Pract; 2010 Jul; 35(7):32-7; quiz 37-8. PubMed ID: 20555242
[No Abstract] [Full Text] [Related]
4. Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy.
Dorey-Stein Z; Amorosa VK; Kostman JR; Lo Re V; Shannon RP
J Cardiometab Syndr; 2008; 3(2):111-4. PubMed ID: 18453812
[No Abstract] [Full Text] [Related]
5. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy.
Resino S; Micheloud D; Lorente R; Bellon JM; Navarro ML; Munoz-Fernandez MA
HIV Med; 2011 Jan; 12(1):54-60. PubMed ID: 20497248
[TBL] [Abstract][Full Text] [Related]
6. [High frequency of dyslipidemia in VIH-infected patients in aa peruvian public hospital].
Rondan PL; Flores-Flores O; Doria NA; Valencia-Mesias G; Chávez-Pérez V; Soria J
Rev Peru Med Exp Salud Publica; 2017; 34(2):239-244. PubMed ID: 29177382
[TBL] [Abstract][Full Text] [Related]
7. [Metabolic and cardiovascular effects of combined antiretroviral therapy in patients with HIV infection. Systematic review of literature].
Casaretti L; Paolillo S; Formisano R; Bologna A; Mattiello G; Conte S; Petraglia L; Lo ludice F; Fabiani I; Cirillo AP; Vitagliano A; Gambardella F; della Ratta GL; Filardi PP
Monaldi Arch Chest Dis; 2011 Dec; 76(4):175-82. PubMed ID: 22567733
[TBL] [Abstract][Full Text] [Related]
8. Antiretroviral and statin drug-drug interactions.
Ray GM
Cardiol Rev; 2009; 17(1):44-7. PubMed ID: 19092370
[TBL] [Abstract][Full Text] [Related]
9. Dyslipidemia in AIDS patients on highly active antiretroviral therapy.
Nery MW; Martelli CM; Turchi MD
Braz J Infect Dis; 2011; 15(2):151-5. PubMed ID: 21503402
[TBL] [Abstract][Full Text] [Related]
10. Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations.
Manfredi R
Clin Infect Dis; 2006 May; 42(9):1345-7; author reply 1347-8. PubMed ID: 16586399
[No Abstract] [Full Text] [Related]
11. Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients.
Calza L; Colangeli V; Manfredi R; Bon I; Re MC; Viale P
J Antimicrob Chemother; 2016 Jun; 71(6):1451-65. PubMed ID: 26846208
[TBL] [Abstract][Full Text] [Related]
12. HIV and highly active antiretroviral therapy: dyslipidemia, metabolic aberrations, and cardiovascular risk.
Zou W; Berglund L
Prev Cardiol; 2007; 10(2):96-103; quiz 104-5. PubMed ID: 17392622
[No Abstract] [Full Text] [Related]
13. [Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features].
Streinu-Cercel A; Ion DA; Chivu LI; Chivu RD
Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):521-5. PubMed ID: 17571539
[TBL] [Abstract][Full Text] [Related]
14. Highly active antiretroviral therapy and dyslipidemia in people living with HIV/AIDS in Fako Division, South West Region of Cameroon.
Nsagha DS; Weledji EP; Assob NJ; Njunda LA; Tanue EA; Kibu OD; Ayima CW; Ngowe MN
BMC Cardiovasc Disord; 2015 Aug; 15():95. PubMed ID: 26315756
[TBL] [Abstract][Full Text] [Related]
15. Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals: a randomized trial.
Lazzaretti RK; Kuhmmer R; Sprinz E; Polanczyk CA; Ribeiro JP
J Am Coll Cardiol; 2012 Mar; 59(11):979-88. PubMed ID: 22402068
[TBL] [Abstract][Full Text] [Related]
16. High-risk dysmetabolism disorders associated with HAART-treated HIV disease, and reimbursement of lipid-lowering drugs, in a clinical and a socio-economic perspective.
Manfredi R
AIDS Rev; 2005; 7(3):155-60. PubMed ID: 16302463
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
Leonard EG; McComsey GA
Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
[TBL] [Abstract][Full Text] [Related]
18. Nutritional therapy to prevent dyslipidemia in patients starting antiretroviral therapy for human immunodeficiency virus.
Stein JH
J Am Coll Cardiol; 2012 Mar; 59(11):989-90. PubMed ID: 22402069
[No Abstract] [Full Text] [Related]
19. HIV-associated dyslipidaemia among HIV antibody-positive patients in Ireland: prevalence and management strategies.
Nolan DP; O'Connor MB; O'Connor C; Moriarty M; O'Leary A; Bergin C
Int J STD AIDS; 2010 Jan; 21(1):75-6. PubMed ID: 19884356
[No Abstract] [Full Text] [Related]
20. [Hypertension, HIV infection, and highly active antiretroviral therapy].
Bernardino de la Serna JI; Zamora FX; Montes ML; García-Puig J; Arribas JR
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):32-7. PubMed ID: 19409669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
